Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

Lancet

Volumn 352, Issue 9123, 1998, Pages 179-184

  Lever, Anthony F ^a   Hole, David J ^b   Gillis, Charles R ^b   McCallum, Iain R ^b   McInnes, Gordon T ^a   MacKinnon, Pauline L ^b   Meredith, Peter A ^a   Murray, Lilian S ^a   Reid, John L ^a   Robertson, James W K ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL;

ADULT; AGED; ARTICLE; CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

EID: 0032543880     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03228-0     Document Type: Article

References (41)

1. 1 Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-99.
2. 2 Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-97.
3. 3 Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Calcium channel blockers and breast carcinoma risk in post-menopausal women. Cancer 1997; 80: 1438-47.
4. 4 Jick H, Jick S, Derby LE, Vasilakis C, Meyers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-28.
5. 5 Ad Hoc Subcommittee of the Liaison Committee of the WHO and the International Society of Hypertension. Effect of calcium antagonists and risk of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15: 105-15.
6. 6 Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL. Cancer risk in users of calcium channel blockers. Hypertension 1997; 29: 1091-94.
7. 7 Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
8. 8 Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk in hypertensive patients taking calcium channel antagonists. J Hypertens 1998; 16: 119-24.
9. 9 Brown JJ, Casals-Stenzel J, Cumming AMM, et al. Angiotensin II, aldosterone and arterial pressure: a quantitative approach. Hypertension 1979; 1: 159-79.
10. 10 Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-79.
11. 11 Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985; 105: 141-45.
12. 12 Le Noble FAC, Kessels-van Wylick LCGA, Hacking WJG, Slaaf DW, Oude Egbrink MGA, Struijker-Boudier HAJ. The role of angiotensin II and prostaglandins in arcade formation in a developing microvascular network. J Vasc Res 1996; 33: 480-88.
13. 13 Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
14. 14 Lindop GBM, Leckie BJ, Mimran A. Renin-secreting tumours. In: Robertson JIS, Nicholls GM, eds. The renin-angiotensin-system. London: Gower Medical Publishing, 1993: 54.
15. 15 Taylor GM, Cook HT, Sheffield EA, Hanson C, Peart WS. Renin in blood vessels in human pulmonary tumors. Am J Pathol 1988; 130: 543-51.
16. 16 Marsigliante S, Resta L, Muscella A, Vinson GP, Marzullo A, Storelli C. AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett 1996; 110: 19-27.
17. 17 Inwang ER, Puddefoot JR, Brown CL, et al. Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 1997; 75: 79-1283.
18. 18 Paquet J-L, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8: 565-72.
19. 19 Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-56.
20. 1 receptor. J Hypertens 1992; 10: 1463-69.
21. 21 Neyses L, Nouskas J, Luyken J, et al. Induction of immediate-early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytes. J Hypertens 1993; 11: 927-34.
22. 22 Sadoshima J-I, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 1993; 73: 424-38.
23. 23 Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991; 196: 280-83.
24. 24 Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene-expression in pancreatic-cancer cells. Proc Soc Exp Biol Med 1995; 210: 221-26.
25. 25 Hii S-I, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77: 880-83.
26. 26 Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 335-36.
27. 27 Isles CG, Walker Lm, Beevers DG, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141-56.
28. 28 Hole DJ, Hawthorne VM, Isles CG, et al. Incidence of and mortality from cancer in hypertensive patients. BMJ 1993; 306: 609-11.
29. 29 Gillis CR, Hole DJ, Lamont D, Boyle P, Graham A. Cancer incidence in the West of Scotland. In: Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents, vol V. Lyons: International Association for Research on Cancer, 1987: 704-07.
30. 30 Hawthorne VM, Greaves DA, Beevers DG. Blood pressure in a Scottish town. BMJ 1974; 3: 600-03.
31. 31 McInnes GT, McGhee SM. Delivery of care for hypertension. J Hum Hypertens 1995; 9: 429-33.
32. 32 WHO International Agency for Research on Cancer. Cancer registration: principles and methods. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, eds. Lyons: IARC Scientific Publications no 95, 1991.
33. 33 Hamet P. Cancer and hypertension: an unresolved issue. Hypertension 1996; 28: 321-24.
34. 34 Members of the Clinic. The Glasgow Blood Pressure Clinic. J R Coll Physicians Lond 1972; 7: 87-97.
35. 35 Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little Brown, 1987: 287.
36. 36 Yeo WW, Foster G, Ramsay LE. Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine. Q J Med 1991; 293: 763-70.
37. 37 Datta M. You cannot exclude the explanation you have not considered. Lancet 1993; 342: 345-47.
38. 38 Leon DA. Failed or misleading adjustment for confounding. Lancet 1993; 342: 479-81.
39. 39 Hansson L. The captopril prevention projects (CAPPP): description and status. Am J Hypertens 1994; 7 (IIS): 82S-83S.
40. 40 Elliott WJ. ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Am J Hypertens 1996; 9: 409-11.
41. 41 Wing LMH, Reid CM, Beilin LJ, et al. Australian comparative outcome trial of angiotensin-converting enzyme inhibitor and diuretic-based treatment of hypertension in the elderly (ANBP2): objective and protocol. Clin Exp Pharmacol Physiol 1997; 24: 188-92.